Australia markets closed

Pediatrix Medical Group, Inc. (MD)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
8.07-0.10 (-1.16%)
As of 02:43PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 687.48M
Enterprise value 1.35B
Trailing P/E N/A
Forward P/E 6.25
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.34
Price/book (mrq)0.80
Enterprise value/revenue 0.68
Enterprise value/EBITDA 72.76

Trading information

Stock price history

Beta (5Y monthly) 1.59
52-week change 3-41.01%
S&P500 52-week change 326.43%
52-week high 315.02
52-week low 37.70
50-day moving average 39.19
200-day moving average 310.63

Share statistics

Avg vol (3-month) 3728.53k
Avg vol (10-day) 3772.56k
Shares outstanding 584.15M
Implied shares outstanding 687.55M
Float 881.68M
% held by insiders 11.37%
% held by institutions 1102.52%
Shares short (15 Apr 2024) 44.6M
Short ratio (15 Apr 2024) 46.22
Short % of float (15 Apr 2024) 47.79%
Short % of shares outstanding (15 Apr 2024) 45.48%
Shares short (prior month 15 Mar 2024) 44.03M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 320 Dec 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -3.53%
Operating margin (ttm)4.92%

Management effectiveness

Return on assets (ttm)4.24%
Return on equity (ttm)-7.99%

Income statement

Revenue (ttm)2B
Revenue per share (ttm)24.24
Quarterly revenue growth (yoy)0.80%
Gross profit (ttm)N/A
EBITDA 189.71M
Net income avi to common (ttm)-70.58M
Diluted EPS (ttm)-0.12
Quarterly earnings growth (yoy)-71.60%

Balance sheet

Total cash (mrq)115.47M
Total cash per share (mrq)1.39
Total debt (mrq)778.66M
Total debt/equity (mrq)90.94%
Current ratio (mrq)1.73
Book value per share (mrq)10.36

Cash flow statement

Operating cash flow (ttm)113.02M
Levered free cash flow (ttm)43.23M